PMID- 12873587
OWN - NLM
STAT- MEDLINE
DCOM- 20030904
LR  - 20051116
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 98
IP  - 7
DP  - 2003 Jul
TI  - Interferon monotherapy for dialysis patients with chronic hepatitis C: an 
      analysis of the literature on efficacy and safety.
PG  - 1610-5
AB  - OBJECTIVE: Hepatitis C virus (HCV) is prevalent in patients with end stage renal 
      disease who are on dialysis. Liver disease from HCV is a cause of substantial 
      morbidity and mortality after kidney transplantation in infected recipients. 
      Effective treatment of chronic HCV is needed in this group of patients. We aimed 
      to determine from the literature the efficacy and safety of interferon 
      monotherapy in dialysis patients with chronic HCV. METHODS: We reviewed the 
      literature from 1986 to 2001 on the efficacy of interferon monotherapy in 
      patients with HCV and end stage renal disease who were on dialysis. The outcomes 
      measured were sustained viral response (SVR) and drop-out rate. RESULTS: We 
      reviewed 17 studies, of which 11 studies with a total of 213 patients met 
      criteria for our analysis. Eight studies evaluated 3 million units (MU) three 
      times/wk (t.i.w.), and three studies evaluated higher doses. The pooled SVR for 3 
      MU was 33% (95% CI = 21-51%). The pooled SVR for genotype 1 patients was 26% (95% 
      CI = 15-37%). Of 152 patients in eight studies treated with 3 MU t.i.w. of 
      interferon monotherapy, 45 patients (29.6%) discontinued therapy because of side 
      effects. CONCLUSIONS: Our analysis suggests that interferon monotherapy is more 
      effective in patients on dialysis than in patients with normal renal function. 
      Interferon monotherapy is associated with more adverse events in dialysis 
      patients. The optimal dose and duration of interferon monotherapy and selection 
      criteria of dialysis patients need to be studied further in clinical trials.
FAU - Russo, Mark W
AU  - Russo MW
AD  - Division of Digestive Diseases and Nutrition, University of North Carolina, 
      Chapel Hill, North Carolina 27599, USA.
FAU - Goldsweig, Craig D
AU  - Goldsweig CD
FAU - Jacobson, Ira M
AU  - Jacobson IM
FAU - Brown, Robert S Jr
AU  - Brown RS Jr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Antiviral Agents)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Antiviral Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Genotype
MH  - Hepacivirus/genetics
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Humans
MH  - Interferons/administration & dosage/adverse effects/*therapeutic use
MH  - Kidney Failure, Chronic/*therapy
MH  - *Renal Dialysis
MH  - Safety
MH  - Treatment Outcome
RF  - 52
EDAT- 2003/07/23 05:00
MHDA- 2003/09/05 05:00
CRDT- 2003/07/23 05:00
PHST- 2003/07/23 05:00 [pubmed]
PHST- 2003/09/05 05:00 [medline]
PHST- 2003/07/23 05:00 [entrez]
AID - S0002927003003083 [pii]
AID - 10.1111/j.1572-0241.2003.07526.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2003 Jul;98(7):1610-5. doi: 10.1111/j.1572-0241.2003.07526.x.